Unknown PHASE4 INTERVENTIONAL 3-arm NCT03105505

The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis

The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial.

Sponsor: Barzilai Medical Center

Conditions Inflammation of the Eyelids

Interventions Fusidic Acid 1% M/R Eye Drops Permethrin 5% Synthomycine 5%

Updated 8 times since 2017 Last updated: Jan 29, 2018 Started: Apr 28, 2017 Primary completion: Sep 30, 2018 Completion: Sep 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Inflammation of the Eyelids, this trial is ongoing. The trial is conducted by Barzilai Medical Center and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Feb 2020 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Enrolling By Invitation → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Enrolling By Invitation PHASE4
Feb 2018 — Jun 2018 [monthly]

Enrolling By Invitation PHASE4
May 2017 — Feb 2018 [monthly]

Enrolling By Invitation PHASE4

First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Barzilai Medical Center

Data source: Barzilai Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ashkelon, Israel